Target Engagement for Intranasal Oxytocin in Autism Spectrum Disorders, an fMRI Dose Response Study
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2017
At a glance
- Drugs Oxytocin (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- 08 May 2017 Status changed from not yet recruiting to recruiting.
- 05 Apr 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.
- 09 Mar 2017 Planned initiation date changed from 1 Mar 2017 to 1 Apr 2017.